Tissue microarray for routine analysis of breast biomarkers in the clinical laboratory

American Journal of Clinical Pathology

Volumn 132, Issue 6, 2009, Pages 899-905

  Thomson, Thomas A ^a   Zhou, Chen ^a   Chu, Christina ^a   Knight, Bryan ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Biomarkers; Breast tumors; Cost savings; Immunohistochemistry; Quality control; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST TUMOR; CLINICAL LABORATORY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OBSERVER VARIATION; PRIORITY JOURNAL; STAINING; TISSUE MICROARRAY; VALIDATION PROCESS;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DNA, NEOPLASM; FEMALE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LABORATORY TECHNIQUES AND PROCEDURES; OBSERVER VARIATION; PATHOLOGY, CLINICAL; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 72949100523     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPW37QGECDYCDO     Document Type: Article

References (11)

1. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
2. Moch H, Kononen T, Kallioniemi OP, et al. Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol. 2001;8:14-20.
3. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res. 1999;5:1966-1975.
4. Graham AD, Faratian D, Rae F, et al. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology. 2008;52:847-855.
5. Sapino A, Marchio C, Senetta R, et al. Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch. 2006;449:288-296.
6. Egervari K, Szollosi Z, Nemes Z. Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract. 2007;203:169-177.
7. Kallioniemi OP, Wagner U, Kononen J, et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet. 2001;10:657-662.
8. Andersen CL, Monni O, Wagner U, et al. High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays. Am J Pathol. 2002;161:73-79.
9. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943-1949.
10. Rimm DL, Camp RL, Charette LA, et al. Tissue microarray: a new technology for amplification of tissue resources. Cancer J. 2001;7:24-31.
11. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.